{
    "nctId": "NCT00853996",
    "briefTitle": "Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer",
    "officialTitle": "Phase II Study of Acolbifene in Pre-Menopausal Women at High Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Gail risk \\>= 1.7% and/or relative risk \\>= 3 times that for 5-year age group\n* Premenopausal\n* More than 6 months since initiating or discontinuing oral contraceptives\n* At increased risk for breast cancer, as indicated by \\>= 1 of the following risk factors:\n* BRCA1/2 mutation characterized as deleterious or of uncertain significance\n* Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ\n* Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia\n* Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:\n\n  * \\>= 4 relatives with breast cancer\n  * \\>= 2 relatives diagnosed with breast cancer at \u2264 50 years of age\n  * Breast and ovarian cancer diagnosed in same relative\n* No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA\n* Exhibits hyperplasia with or without atypia (Masood score \\>= 14) with \\>= 500 cells AND Ki-67 positivity \\>= 2% by RPFNA performed within 6 months prior to initiation of study drug\n* Estimated visual mammographic breast density category \\>= 5% on mammogram performed within 6 months prior to initiation of study drug\n* Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits\n* Absolute granulocyte count \\> 1,000/mm\\^3\n* Platelets \\> 100,000/mm\\^3\n* Hemoglobin \\> 10 g/dL\n* Bilirubin \\< 2.0 mg/dL\n* AST \\< 2 times upper limit of normal (ULN)\n* Albumin \\> 3.0 g/dL\n* Creatinine \\< 1.5 mg/dL\n* Alkaline phosphatase \\< 2 times ULN\n* Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)\n* Negative pregnancy test prior to receiving study agent\n\nExclusion Criteria\n\n* pregnant or nursing\n* nursing within the past 6 months\n* Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)\n* History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes\n* History of deep venous thrombosis\n* History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent\n* Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA\n* Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)\n* Other concurrent chemopreventive agents\n* Concurrent anticoagulants\n* Other concurrent investigational agents\n* Bilateral breast implants",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT"
}